DURECT Corporation (DRRX) News

DURECT Corporation (DRRX)

Today's Latest Price: $1.85 USD

0.09 (5.11%)

Updated Sep 18 4:00pm

Add DRRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 232 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter DRRX News Items

DRRX News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest DRRX News From Around the Web

Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

Durect (DRRX) Investor Presentation - Slideshow

The following slide deck was published by DURECT Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | August 28, 2020

Oppenheimer: These 3 “Strong Buy” Stocks Could Double, If Not More

The “dog days” of summer are here, but it’s just as busy as ever on the Street. As earnings results continue to roll in, investors will be watching for any update on the next economic stimulus package along with the non-farm payroll report slated for release this Friday. Against this backdrop, plenty of questions remain, weighing on the minds of both institutional and private investors.In a recent note to clients, Oppenheimer’s Chief Investment Strategist John Stoltzfus addresses these concerns. When it comes to stocks’ disconnected state, he writes that the market tends to focus on the future, with it betting on a successful outcome based on the stimulus policy already put in place. But will this highly accommodative monetary policy eventually cause inflation?“We do not expect high lev...

Yahoo | August 5, 2020

DURECT to Present at the BTIG Biotechnology Conference 2020

DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D; will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT. Institutional investors that are participating in the conference may request a virtual one-on-one meeting through the conference coordinators.

Yahoo | August 5, 2020

DURECT Corporation (DRRX) CEO Jim Brown on Q2 2020 Results - Earnings Call Transcript

DURECT Corporation (DRRX) Q2 2020 Earnings Conference Call August 03, 2020 04:30 PM ET Company Participants Mike Arenberg - Chief Financial Officer Jim Brown - President & Chief Executive Officer WeiQi Lin - Executive Vice President, Research & Development & Principal Scientist Conference Call Participants Ellie Merle - Cantor Fitzgerald...

SA Transcripts on Seeking Alpha | August 4, 2020

Durect Corp (DRRX) Q2 2020 Earnings Call Transcript

DRRX earnings call for the period ending June 30, 2020.

Yahoo | August 4, 2020

Durect EPS beats by $0.06, beats on revenue

Durect (DRRX): Q2 GAAP EPS of $0.07 beats by $0.06.Revenue of $25.84M (+547.6% Y/Y) beats by $10.27M.Shares +0.21%.Press Release...

Seeking Alpha | August 3, 2020

Durect (DRRX) Q2 Earnings and Revenues Beat Estimates

Durect (DRRX) delivered earnings and revenue surprises of 75.00% and 30.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 3, 2020

DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update.

Yahoo | August 3, 2020

Is It Too Late to Buy These 3 Pharmaceutical Stocks?

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Yahoo | July 7, 2020

DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

DURECT Corporation (Nasdaq: DRRX) today announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The trial will enroll approximately 80 patients.

Yahoo | July 1, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5241 seconds.